Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 32 of the 48 sources its claims cite were checked for support.

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Open access

Published version of a preprint

Abstract

PURPOSE: Navtemadlin is a potent small-molecule inhibitor of MDM2, which has completed a phase 0 window-of-opportunity study in glioblastoma (GBM). To optimally interpret the clinical data, a detailed analysis of navtemadlin pharmacokinetics (PK), pharmacodynamics, and efficacy was performed in GBM patient-derived xenografts (PDX). EXPERIMENTAL DESIGN: Response to navtemadlin was characterized in vitro and in vivo in GBM PDXs with and without MDM2 amplification. Efficacy in vivo was integrated with measured plasma and intra-tumoral drug levels to develop a translational PK/efficacy model comparing exposure effective in PDX to exposure achieved in phase 0 patient samples. RESULTS: In vitro, navtemadlin showed robust on-target activity in TP53-wild-type GBM. In vivo efficacy strongly correlated with MDM2 amplification status. In subcutaneous PDXs, navtemadlin significantly extended survival when dosed at 25 mg/kg in an MDM2-amplified PDX compared with 100 mg/kg in a non-amplified PDX. Central nervous system distribution was limited by blood-brain barrier efflux (Kp_brain = 0.009). In an MDM2-amplified orthotopic PDX model, navtemadlin was ineffective at 100 mg/kg; when established in mice with deficient blood-brain barrier efflux (Rag-/-Abcb1a-/-Abcg2-/-), 25 mg/kg doubled survival. A tumor PK/efficacy model was built to define target exposure for efficacy in GBM, using the effective 25 mg/kg dose. Modeled exposures exceeded this threshold in three (of 16) tumor samples from phase 0 study patients at the 240 mg dose level. CONCLUSIONS: Navtemadlin efficacy was highly dependent on adequate brain penetration. Our translational PK/efficacy model suggests that the minimum effective tumor exposures were achieved only in a minority of patients with GBM.

Overview

CoChat Summary

TL;DR

Navtemadlin shows on-target activity in TP53–wild-type glioblastoma PDXs, with greatest efficacy in MDM2-amplified tumors, but central nervous system delivery is severely limited by P-gp efflux. A translational PK/efficacy model suggests the minimum effective tumor exposure was achieved in only a minority of phase 0 GBM patient samples.

Key findings

  • In vitro, navtemadlin reduced viability in five TP53WT PDXs; TP53MUT GBM120 was resistant and MDM4-amplified GBM8 showed limited response, with EC50 ≤100 nmol/L for TP53WT PDXs except GBM8.
  • In a 1×1×1 subcutaneous PDX trial across 15 PDXs, TP53/MDM2 status correlated with response (P = 0.007); MDM2-amplified tumors showed complete durable responses, with recurrence >100 days after dosing in 2 of 4 and 20.1- to 27.8-fold time-to-endpoint extension, versus 1.9- to 4.8-fold in TP53WT MDM2–non-amplified models.
  • In subcutaneous GBM108, 25 mg/kg extended median time to endpoint versus vehicle (61 vs. 11 days, P = 0.014), while 100 mg/kg caused regression; in GBM14, only 100 mg/kg extended time to endpoint (37 vs. 12.5 days, P = 0.003).
  • CNS distribution was limited: Kp_brain = 0.009 in wild-type mice, rising to 0.31 in P-gp/Bcrp-deficient mice (~35-fold higher). Orthotopic GBM108 showed no significant efficacy in wild-type mice, but in DKO mice median survival was 62 days for vehicle, 83 days for 10 mg/kg, 132 days for 25 mg/kg, and >225 days for 100 mg/kg. The modeled minimum effective tumor exposure was AUC_tumor = 2,800 hour*ng/mL; phase 0 samples reaching this threshold were 1 of 16 at 120 mg and 4 of 16 at 240 mg in the Results (the abstract states 3 of 16 at 240 mg).

Methods

  • In vitro assays in GBM PDX short-term cultures included viability, Western blotting, qRT-PCR, IncuCyte live-cell imaging, and immunofluorescence; in vivo studies used subcutaneous 1×1×1 screening across 15 PDXs and powered subcutaneous studies in GBM108, GBM148, and GBM14, plus orthotopic GBM108, GBM39, and GBM148 models in athymic nude and Rag1−/−Abcb1a−/−Abcg2−/− DKO mice.
  • Drug levels were measured by LC/MS-MS and MALDI-MSI, with PD readouts by IHC, qRT-PCR, and t-CyCIF; unbound fractions were measured by rapid equilibrium dialysis, and PK parameters by noncompartmental analysis.
  • A translational PK/efficacy model was built in SAAM II using GBM108 subcutaneous tumor/plasma data at the effective 25 mg/kg dose and phase 0 patient tumor-to-plasma ratios; survival comparisons used Kaplan–Meier and log-rank tests, with P < 0.05 considered significant.

Limitations

  • The paper states that the PK/efficacy model assumes navtemadlin PK parameters are equivalent in healthy FVB mice and PDX-bearing nude mice, that tumor-to-plasma ratio is constant over 24 hours in mice and patients, and that target exposure was defined from monotherapy PDX efficacy, which may differ for combination with radiation.
  • The paper states that the 1×1×1 design uses subcutaneous tumors, differing from the orthotopic tumor microenvironment, and that PD effects could not be incorporated into the model because p53 target gene upregulation was highly variable and poorly correlated with efficacy.
  • Evident from the text: the abstract and Results report different numbers of 240 mg phase 0 samples reaching the target exposure (3 of 16 vs. 4 of 16), and the phase 0 plasma sampling had limited time points that were not sufficient to develop a robust human exposure model.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-25-0244

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Effects of navtemadlin in vitro. A, Effects of navtemadlin on cell viability. Short-term explant cultures were treated with varying doses of navtemadlin (0–100 nmol/L) and cell viability was measured after 7 days using CellTiter-Glo 3D assay. Amp, amplified; non-amp, non-amplified. B–F, Effects of navtemadlin on the p53 pathway. Short-term cultures were treated with navtemadlin (0–100 nmol/L) ± 5 Gy radiation and collected at 6 hours. The expression of p53 target genes was evaluated by (B) Western blotting and (C–E) qRT-PCR. At least three independent experiments were performed for each PDX with mean ± SEM shown. Effects of navtemadlin (30 nmol/L) ± radiation (RT) on (F) confluence and (G) cell death (YOYO-3 fluorescence) were measured over 72 hours using the IncuCyte live cell imaging system. Data from 2 to 3 independent experiments were normalized to untreated controls with mean ± SEM shown. *, P < 0.05; **, P < 0.01.
Figure 1. Effects of navtemadlin in vitro. A, Effects of navtemadlin on cell viability. Short-term explant cultures were treated with varying doses of navtemadlin (0–100 nmol/L) and cell viability was measured after 7 days using CellTiter-Glo 3D assay. Amp, amplified; non-amp, non-amplified. B–F, Effects of navtemadlin on the p53 pathway. Short-term cultures were treated with navtemadlin (0–100 nmol/L) ± 5 Gy radiation and collected at 6 hours. The expression of p53 target genes was evaluated by (B) Western blotting and (C–E) qRT-PCR. At least three independent experiments were performed for each PDX with mean ± SEM shown. Effects of navtemadlin (30 nmol/L) ± radiation (RT) on (F) confluence and (G) cell death (YOYO-3 fluorescence) were measured over 72 hours using the IncuCyte live cell imaging system. Data from 2 to 3 independent experiments were normalized to untreated controls with mean ± SEM shown. *, P < 0.05; **, P < 0.01.CC BY-NC-ND · PubMed Central
Figure 2. Response to navtemadlin in a 1 × 1 × 1 PDX preclinical trial. A, Mice with established subcutaneous tumors (one animal per treatment group) were treated with vehicle or navtemadlin (100 mg/kg daily) for 4 weeks and tumor growth was monitored until reaching the defined endpoint of three-times initial volume. (+) is indicating that tumor did not recur. B, Ratio of time to endpoint for navtemadlin- to vehicle-treated tumors. Open symbols (◊) are indicating that tumor did not recur. C and D, Mice with established subcutaneous tumors (one animal per treatment group) were treated with one dose of vehicle or navtemadlin (100 mg/kg), tumor tissue was harvested after 24 hours, and expression of p53 target genes (CDKN1A, BBC3, and FAS) was evaluated by qRT-PCR. P value from a rank-sum test. Amp, amplified; non-amp, non-amplified.
Figure 2. Response to navtemadlin in a 1 × 1 × 1 PDX preclinical trial. A, Mice with established subcutaneous tumors (one animal per treatment group) were treated with vehicle or navtemadlin (100 mg/kg daily) for 4 weeks and tumor growth was monitored until reaching the defined endpoint of three-times initial volume. (+) is indicating that tumor did not recur. B, Ratio of time to endpoint for navtemadlin- to vehicle-treated tumors. Open symbols (◊) are indicating that tumor did not recur. C and D, Mice with established subcutaneous tumors (one animal per treatment group) were treated with one dose of vehicle or navtemadlin (100 mg/kg), tumor tissue was harvested after 24 hours, and expression of p53 target genes (CDKN1A, BBC3, and FAS) was evaluated by qRT-PCR. P value from a rank-sum test. Amp, amplified; non-amp, non-amplified.CC BY-NC-ND · PubMed Central
Figure 3. Efficacy, drug distribution, and PD response in GBM108 and GBM14 subcutaneous PDX. Mice with established (A) GBM108 or (B) GBM14 subcutaneous tumors were randomized to treatment with navtemadlin (0, 10, 25, or 100 mg/kg) daily for 4 weeks (n = 5 per group). Tumor volume was monitored three times weekly until reaching 3× the initial tumor volume. One animal (#) was excluded from statistical analysis because of lack of tumor growth. C–H, For PK and PD studies, mice were treated with two consecutive daily doses of navtemadlin (n = 5 per group), with samples collected 2 hours after the second dose. Levels of navtemadlin were measured by LC/MS-MS in plasma and tumor from (C) GBM108 or (D) GBM14 PDX. Upregulation of p53 target genes in (E) GBM108 and (F) GBM14 tumor tissue was evaluated by qRT-PCR, with values for individual samples (n = 5 per group) shown. Effects of navtemadlin on p21 expression, cell proliferation (Ki67 labeling), and apoptosis (TUNEL staining) were assessed by IHC in (G) GBM108 and (H) GBM14 formalin-fixed, paraffin-embedded tissues. *, P < 0.05; **, P < 0.01; ***, P < 0.001. RQ, relative quantification.
Figure 3. Efficacy, drug distribution, and PD response in GBM108 and GBM14 subcutaneous PDX. Mice with established (A) GBM108 or (B) GBM14 subcutaneous tumors were randomized to treatment with navtemadlin (0, 10, 25, or 100 mg/kg) daily for 4 weeks (n = 5 per group). Tumor volume was monitored three times weekly until reaching 3× the initial tumor volume. One animal (#) was excluded from statistical analysis because of lack of tumor growth. C–H, For PK and PD studies, mice were treated with two consecutive daily doses of navtemadlin (n = 5 per group), with samples collected 2 hours after the second dose. Levels of navtemadlin were measured by LC/MS-MS in plasma and tumor from (C) GBM108 or (D) GBM14 PDX. Upregulation of p53 target genes in (E) GBM108 and (F) GBM14 tumor tissue was evaluated by qRT-PCR, with values for individual samples (n = 5 per group) shown. Effects of navtemadlin on p21 expression, cell proliferation (Ki67 labeling), and apoptosis (TUNEL staining) were assessed by IHC in (G) GBM108 and (H) GBM14 formalin-fixed, paraffin-embedded tissues. *, P < 0.05; **, P < 0.01; ***, P < 0.001. RQ, relative quantification.CC BY-NC-ND · PubMed Central
Figure 4. Efficacy, drug distribution, and PD response in orthotopic GBM108 PDX. Orthotopic GBM108 tumors were established in (A) wild-type or (B) DKO (Abcb1a−/−Abcg2−/−) mice. Mice were randomized to treatment with navtemadlin (0, 10, 25, or 100 mg/kg) daily for 4 weeks (n = 10 per group) and monitored until moribund. C–I, Mice were treated with two doses of navtemadlin and samples collected 2 hours after the second dose. Effects of navtemadlin on p21 expression, cell proliferation (Ki67 labeling), and apoptosis (TUNEL) were evaluated by IHC in formalin-fixed, paraffin-embedded tissue sections from (C) wild-type or (D) DKO mice. Concentrations of navtemadlin were measured by MALDI-MSI in tumor and normal brain in (E) wild-type or (G) DKO mice. The expression of p53 target genes was evaluated by qRT-PCR in matched frozen tumor tissue from (F) wild-type or (H) DKO mice. I, Spatial analyses were performed on serial brain sections from representative DKO mice. From left to right, tumor hematoxylin and eosin (H&E) staining, spatial distribution of navtemadlin levels quantified by MALDI-MSI (navtemadlin), nuclei (Hoechst) highlighting the region of interest characterized by t-CyCIF technique, and t-CyCIF analysis of p53 targets (p53, p21, and MDM2) and effectors (p53, Ki67, and cCASP3). J, Effects of navtemadlin on p21, p53, Ki67, cCASP3, and MDM2 as quantified by t-CyCIF. *, P < 0.05; **, P < 0.01; ***, P < 0.001. RQ, relative quantification.
Figure 4. Efficacy, drug distribution, and PD response in orthotopic GBM108 PDX. Orthotopic GBM108 tumors were established in (A) wild-type or (B) DKO (Abcb1a−/−Abcg2−/−) mice. Mice were randomized to treatment with navtemadlin (0, 10, 25, or 100 mg/kg) daily for 4 weeks (n = 10 per group) and monitored until moribund. C–I, Mice were treated with two doses of navtemadlin and samples collected 2 hours after the second dose. Effects of navtemadlin on p21 expression, cell proliferation (Ki67 labeling), and apoptosis (TUNEL) were evaluated by IHC in formalin-fixed, paraffin-embedded tissue sections from (C) wild-type or (D) DKO mice. Concentrations of navtemadlin were measured by MALDI-MSI in tumor and normal brain in (E) wild-type or (G) DKO mice. The expression of p53 target genes was evaluated by qRT-PCR in matched frozen tumor tissue from (F) wild-type or (H) DKO mice. I, Spatial analyses were performed on serial brain sections from representative DKO mice. From left to right, tumor hematoxylin and eosin (H&E) staining, spatial distribution of navtemadlin levels quantified by MALDI-MSI (navtemadlin), nuclei (Hoechst) highlighting the region of interest characterized by t-CyCIF technique, and t-CyCIF analysis of p53 targets (p53, p21, and MDM2) and effectors (p53, Ki67, and cCASP3). J, Effects of navtemadlin on p21, p53, Ki67, cCASP3, and MDM2 as quantified by t-CyCIF. *, P < 0.05; **, P < 0.01; ***, P < 0.001. RQ, relative quantification.CC BY-NC-ND · PubMed Central
Figure 5. Translational PK–efficacy model. A–C, Modeling of effective tumor exposure in PDX. Target exposure was modeled on tumor/plasma concentrations measured in GBM108 subcutaneous PDX dosed at 25 mg/kg, the lowest dose level providing significant survival benefit (see Fig. 3). A, Mouse plasma exposure model was fit on measured plasma concentrations in FVB mice at 20 mg/kg oral dosing. B, Tumor-to-plasma ratio was measured in GBM108 subcutaneous PDX after 10, 25, and 100 mg/kg oral dosing. C, Tumor exposure over 7 days was modeled by multiplying plasma exposure by the average tumor-to-plasma ratio (1.14). The model predicted minimum effective exposure (AUC_tumor) to be 2,800 hour*ng/mL. D–H, Modeling navtemadlin exposure in GBM phase 0 patient samples. D, Plasma exposure was simulated based on the first-in-human (FIH) phase I study (NCT01723020). Arrows represent the drug dose. Red dots are observed (obs) plasma concentrations at 240 mg in the FIH study; blue open circles are observed plasma concentrations at 240 mg in the GBM phase 0 study (NCT03107780). E, Tumor-to-plasma ratios were calculated for tissue from CE and NCE regions from each patient in the GBM phase 0 study. F, Patient tumor exposure in CE and NCE tumors was modeled by multiplying plasma exposure by the tumor-to-plasma ratio. The median exposure is shown. G and H, Patient tumor exposure (AUC_tumor) modeled for each patient in the phase 0 study relative to the target exposure of 2,800 hour*ng/mL.
Figure 5. Translational PK–efficacy model. A–C, Modeling of effective tumor exposure in PDX. Target exposure was modeled on tumor/plasma concentrations measured in GBM108 subcutaneous PDX dosed at 25 mg/kg, the lowest dose level providing significant survival benefit (see Fig. 3). A, Mouse plasma exposure model was fit on measured plasma concentrations in FVB mice at 20 mg/kg oral dosing. B, Tumor-to-plasma ratio was measured in GBM108 subcutaneous PDX after 10, 25, and 100 mg/kg oral dosing. C, Tumor exposure over 7 days was modeled by multiplying plasma exposure by the average tumor-to-plasma ratio (1.14). The model predicted minimum effective exposure (AUC_tumor) to be 2,800 hour*ng/mL. D–H, Modeling navtemadlin exposure in GBM phase 0 patient samples. D, Plasma exposure was simulated based on the first-in-human (FIH) phase I study (NCT01723020). Arrows represent the drug dose. Red dots are observed (obs) plasma concentrations at 240 mg in the FIH study; blue open circles are observed plasma concentrations at 240 mg in the GBM phase 0 study (NCT03107780). E, Tumor-to-plasma ratios were calculated for tissue from CE and NCE regions from each patient in the GBM phase 0 study. F, Patient tumor exposure in CE and NCE tumors was modeled by multiplying plasma exposure by the tumor-to-plasma ratio. The median exposure is shown. G and H, Patient tumor exposure (AUC_tumor) modeled for each patient in the phase 0 study relative to the target exposure of 2,800 hour*ng/mL.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

23 Valid · 4 Not valid · 9 Not checked · 126 Own results and interpretations

91 more claims · 5 with their cited sources checked

Create a free account to see all 162 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 45 references

Cited by

See all 3

Metadata

Authors
Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., Hossain, M. A., Decker, P. A., Kosel, M. L., Gupta, S. K., Jain, S., Sarkaria, P. P., Hu, Z., Ott, L. L., Carlson, B. L., Bakken, K. K., Talele, S., Zhang, W., Ligon, K. L., Lee, E. Q., Eckel Passow, J. E., Burgenske, D. M., Agar, N. Y. R., Elmquist, W. F., & Sarkaria, J. N.
Affiliations
  • Mayo Clinic (US)
  • University of Minnesota (US)
  • Brigham and Women's Hospital (US)
  • 1Mayo Clinic, Rochester, Minnesota.
  • Harvard University (US)
Corresponding author
Sarkaria, Jann N.
Venue
Clinical Cancer Research
Published
2025-07-01
Volume
31
Issue
17
Pages
3771-3786
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4411871462
Cited by
2
References
45
Citations by year
2026: 1 · 2025: 1
FWCI
1.28
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Funders
  • National Cancer Institute (U19CA264362, U01CA227954, R01CA285536, U19 CA264504, R01CA262462, UM1 CA137443)
  • William H. Donnor Professorship
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
MDM2 inhibitors, glioblastoma, IDH-wildtype glioblastoma, patient-derived xenografts, pharmacokinetics, pharmacodynamics, MDM2 amplification, brain penetration, TP53
MeSH terms
ATP Binding Cassette Transporter, Subfamily G, Member 2, Animals, Antineoplastic Agents, Brain Neoplasms, Disease Models, Animal, Female, Glioblastoma, Humans, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-25-0244
The paper
Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., Hossain, M. A., Decker, P. A., Kosel, M. L., Gupta, S. K., Jain, S., Sarkaria, P. P., Hu, Z., Ott, L. L., Carlson, B. L., . . . Sarkaria, J. N. (2025). Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-0244

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.